Amylyx says Government of Quebec to cover ALBRIOZA for ALS

Amylyx Pharmaceuticals Canada announced that the company has entered into a Product Listing Agreement with Quebec for the public reimbursement of ALBRIOZA, effective July 6, 2023. The treatment will be included on the List of Medications reimbursed under Regie de l’assurance maladie du Quebec, or RAMQ, for the treatment of amyotrophic lateral sclerosis, or ALS, often known as Lou Gehrig’s disease or maladie de Charcot. In the CENTAUR clinical trial, ALBRIOZA was shown to significantly slow disease progression and loss of functional decline in people living with ALS, potentially giving them more time with functional independence. Amylyx is currently working with other provincial, territorial and federal drug plans to have ALBRIOZA listed on public formularies across the country.